GlassScriptPhysician profile
Ekta B Shah
NPI 1063607901
$1,845.39
in general payments reported to CMS, 2019-2025
10 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.96 · 2022: $122 · 2023: $189 · 2024: $1,354 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Travel and Lodging: $568 · Honoraria: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.97 |
| Travel and Lodging | $567.64 |
| Honoraria | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $992.89 | 2024 | |
| Aimmune Therapeutics, INC. | $199.96 | 2021-2024 | |
| Genentech USA, INC. | $140.43 | 2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $127.90 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2023 | Tezspire |
| Alexion Pharmaceuticals, INC. | $121.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $60.14 | 2023-2025 | Dupixent |
| Pfizer INC. | $37.86 | 2023-2024 | |
| Greer Laboratories, INC. | $24.42 | 2024 | Palforzia |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2023 | Cuvitru |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekta Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.